Clinical trial
Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With…
NCT00263874 · Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00263874 |
|---|---|
| Title | Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD |
| Official title | A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of UK-500,001 Dry Powder For Inhalation (DPI) In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD). |
| Lead sponsor | Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pulmonary Disease, Chronic Obstructive |
| Intervention type | Drug |
| Interventions | UK-500, 001 |
| Enrollment | 324 |
| Start date | Nov 1, 2005 |
| Completion | Sep 1, 2006 |
| First posted | Dec 9, 2005 |
| Last update posted | Jul 23, 2007 |
| Countries | Argentina, Australia, Canada, Chile, Croatia, Czechia, Hungary, Singapore, Spain, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: